FR2790955B1 - Utilisation d'oligonucleotides stabilises comme principe actif antitumoral - Google Patents

Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Info

Publication number
FR2790955B1
FR2790955B1 FR9903433A FR9903433A FR2790955B1 FR 2790955 B1 FR2790955 B1 FR 2790955B1 FR 9903433 A FR9903433 A FR 9903433A FR 9903433 A FR9903433 A FR 9903433A FR 2790955 B1 FR2790955 B1 FR 2790955B1
Authority
FR
France
Prior art keywords
active ingredient
stabilized oligonucleotides
tumor active
oligonucleotides
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9903433A
Other languages
English (en)
French (fr)
Other versions
FR2790955A1 (fr
Inventor
Antoine Carpentier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9903433A priority Critical patent/FR2790955B1/fr
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to US09/937,057 priority patent/US7700569B1/en
Priority to EP00910993A priority patent/EP1162982B9/fr
Priority to PT00910993T priority patent/PT1162982E/pt
Priority to ES00910993T priority patent/ES2235839T3/es
Priority to DK00910993T priority patent/DK1162982T3/da
Priority to CA002371990A priority patent/CA2371990A1/fr
Priority to DE60018050T priority patent/DE60018050T2/de
Priority to JP2000606246A priority patent/JP2002539265A/ja
Priority to AU33006/00A priority patent/AU3300600A/en
Priority to AT00910993T priority patent/ATE288759T1/de
Priority to PCT/FR2000/000676 priority patent/WO2000056342A2/fr
Publication of FR2790955A1 publication Critical patent/FR2790955A1/fr
Priority to US09/967,881 priority patent/US7108844B2/en
Application granted granted Critical
Publication of FR2790955B1 publication Critical patent/FR2790955B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
FR9903433A 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral Expired - Fee Related FR2790955B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
AT00910993T ATE288759T1 (de) 1999-03-19 2000-03-17 Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln
PT00910993T PT1162982E (pt) 1999-03-19 2000-03-17 Utilizacao de oligonucleotidos estabilizados pata a preparacao de um meicamento com accao anti-tumor
ES00910993T ES2235839T3 (es) 1999-03-19 2000-03-17 Uso de oligonucleotidos estabilizados para la preparacion de un medicamento de accion antitumoral.
DK00910993T DK1162982T3 (da) 1999-03-19 2000-03-17 Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
CA002371990A CA2371990A1 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
US09/937,057 US7700569B1 (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumor activity
JP2000606246A JP2002539265A (ja) 1999-03-19 2000-03-17 抗腫瘍活性を有する薬剤を製造するための安定化オリゴヌクレオチドの使用
AU33006/00A AU3300600A (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
EP00910993A EP1162982B9 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
DE60018050T DE60018050T2 (de) 1999-03-19 2000-03-17 VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn
US09/967,881 US7108844B2 (en) 1999-03-19 2001-09-28 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Publications (2)

Publication Number Publication Date
FR2790955A1 FR2790955A1 (fr) 2000-09-22
FR2790955B1 true FR2790955B1 (fr) 2003-01-17

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9903433A Expired - Fee Related FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Country Status (12)

Country Link
US (2) US7700569B1 (https=)
EP (1) EP1162982B9 (https=)
JP (1) JP2002539265A (https=)
AT (1) ATE288759T1 (https=)
AU (1) AU3300600A (https=)
CA (1) CA2371990A1 (https=)
DE (1) DE60018050T2 (https=)
DK (1) DK1162982T3 (https=)
ES (1) ES2235839T3 (https=)
FR (1) FR2790955B1 (https=)
PT (1) PT1162982E (https=)
WO (1) WO2000056342A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP1765361A2 (fr) * 2004-06-25 2007-03-28 Institut Gustave Roussy Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
EP1649859A1 (fr) * 2004-10-22 2006-04-26 Institut Gustave Roussy Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
US7943591B2 (en) * 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
WO1993005182A1 (en) 1991-09-05 1993-03-18 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
WO1995002051A2 (en) * 1993-07-10 1995-01-19 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
JP2001505401A (ja) * 1993-09-20 2001-04-24 シー． リード，ジョン ｂｃ１−２遺伝子発現の調節
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
DE69708878T2 (de) 1996-05-22 2002-07-25 Mcgill University, Montreal Spezifische inhibitoren vom dna-methyltransferaseenzym
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
EP1003850B1 (en) * 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
DE69829984D1 (de) 1997-08-29 2005-06-02 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
WO2000062923A1 (en) 1999-04-19 2000-10-26 Engelhard Corporation Catalyst composition comprising ceria and a platinum group metal
WO2001051061A1 (en) * 2000-01-14 2001-07-19 Intrabiotics Pharmaceuticals, Inc. Derivatives of polyene macrolides and preparation and use thereof

Also Published As

Publication number Publication date
AU3300600A (en) 2000-10-09
EP1162982B9 (fr) 2005-07-06
ATE288759T1 (de) 2005-02-15
DE60018050T2 (de) 2006-02-23
ES2235839T3 (es) 2005-07-16
DE60018050D1 (de) 2005-03-17
US7700569B1 (en) 2010-04-20
US20020192184A1 (en) 2002-12-19
FR2790955A1 (fr) 2000-09-22
JP2002539265A (ja) 2002-11-19
US7108844B2 (en) 2006-09-19
EP1162982A2 (fr) 2001-12-19
CA2371990A1 (fr) 2000-09-28
PT1162982E (pt) 2005-05-31
EP1162982B1 (fr) 2005-02-09
WO2000056342A2 (fr) 2000-09-28
DK1162982T3 (da) 2005-06-13
WO2000056342A3 (fr) 2001-07-26

Similar Documents

Publication Publication Date Title
FR2790955B1 (fr) Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
HUP0104573A2 (hu) Agrokémiai készítmények
WO2001093841A3 (en) Barbituric acid analogs as therapeutic agents
MXPA03007712A (es) Sales farmaceuticas.
NO995817D0 (no) Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
MX9700885A (es) Nuevas heteroariloxazolidinonas.
IL190905A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
EE05434B1 (et) Farmatseutiliselt aktiivsed uridiiniestrid
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
EP1445253A4 (en) 4,4-DIFLUOR-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES AND THEIR SALTS
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
IT1318667B1 (it) Medicamento antinfiammatorio.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
EP1062948A4 (en) DRUGS AGAINST CARDIAC DIASTOLIC DISORDERS
ATE308984T1 (de) Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
DE50010009D1 (en) Hydroxamsäurederivate
ES2179668T3 (es) Un compuesto wf002, su produccion y su uso.
MXPA02002486A (es) Uso de dexrazoxano para tratar la psoriasis.
CA2353909A1 (en) Betacellulin muteins
WO2001041543A3 (en) Pesticidal activity of functionalized alkenes

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20161130